Possibilities of using cytoprotectors in complex therapy of chronic coronary heart disease

Mikhin V.P.; Borovkova N.Yu.; Shulyndin A.V.

doi:https://doi.org/10.17116/kardio202417041410

Close metadata

Recommended articles:

Arterial hypertension is an oxidative stress, as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):84-90

Psoriasis: analysis of comorbid pathology. Russian Journal of Clinical Dermatology and Venereology. 2025;(1):16-21

Neuroprotective therapy of glaucoma. Russian Annals of Ophthalmology. 2025;(1):83-90

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112

Personal characteristics of patients with cerebral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56

Sleep deprivation and the development of oxidative stress in animal models. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):124-129

Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Therapeutic potential of quercetin and its derivatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50

Abstract:

The chronic form of coronary heart disease (CHD) is one of the most common types of cardiovascular pathology in the Russian Federation. The main causes of myocardial ischemia are a decrease in coronary reserve, as well as a decrease in coronary blood flow due to atherosclerotic stenosis. When cardiac muscle perfusion is impaired, energy deficiency occurs in cardiomyocytes and an ischemic cascade develops, leading to oxidative stress. In conditions of chronic ischemia in ischemic heart disease, therapy should be aimed at maintaining the energy-synthesizing function of mitochondria by activating the least energy- and oxygen-consuming pathways of ATP synthesis, combating oxidative stress and preventing the death of cardiomyocytes. Cytoprotector drugs meet these requirements. One of their most famous representatives is Mexidol — original (biological reference medicine) ethylmethylhydroxypyridine succinate. Anti-ischemic action is achieved by combining of antioxidant, antihypoxic and membrane-stabilizing pharmacological effects. The review presents the experience of using ethylmethylhydroxypyridine succinate in patients with chronic ischemic heart disease from the perspective of studying their effectiveness and safety using clinical, instrumental and laboratory research methods.

Keywords:

chronic form of coronary heart disease (CHD)

energy deficiency

oxidative stress

cytoprotectors

ethylmethylhydroxypyridine succinate

mexidol

Authors:

Mikhin V.P.

Kursk State Medical University

ORCID: 0000-0002-5398-9727

Borovkova N.Yu.

Privolzhsky Research Medical University

ORCID: 0000-0001-7581-4138

Shulyndin A.V.

LLC «Ordinatsiya»

ORCID: 0000-0003-2822-9934

Received:

10.06.2024

Accepted:

29.06.2024

Close metadata

References:

Health care In Russia. 2023: statistical collection/Rosstat. M. Z-46 2023;179s. The reference is active on 31.05.24. https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf
Orlov IN. The results of the clinical activity of the Institute for Coronary and Vascular Surgery of Bakoulev National Medical Research Center for Cardiovascular Surgery in 2019. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2020;21(4):446-452. (In Russ.). https://doi.org/10.24022/1810-0694-2020-21-4-446-452
Guide to cardiology: under the editorship of the academician E.I. Chazov. In 4 T. M.: Praktika publishing house; 2014. (In Russ.).
Cardiology: national leaders: under the editorship of E.V. Shlyakhto. the 2nd prod., reslave. and additional M.: GEOTAR-media; 2015. (In Russ.).
2020 Clinical practice guidelines for Stable coronary artery disease. Russian Journal of Cardiology. 2020;25(11):4076. (In Russ.). https://doi.org/10.15829/1560-4071-2020-4076.
Gilyarevsky SR, Kosolapov DL, Lopotovsky PYu. Stressful cardiomyopathy or cardiomyopathy of Takotsubo. Heart failure. 2010;11:59-61; 306-313. (In Russ.).
Vershinina SV, Akarachkova ES. Anxiety in the general practice and its treatment. RMZh. 2011;18:1161. (In Russ.).
Karpov YuA, Kukharchuk VV, Lyakishev AA et al. Diagnosis and treatment of chronic ischemic heart disease. Kardiologicheskiy vestnik. 2015;10:3:3-33. (In Russ.).
Mikhin VP, Nikolenko TA, Gromnatsky NI. The role of cytoprotectors in the treatment of patients with chronic forms of coronary heart disease. Therapy. 2021;7:4(46). (In Russ.). https://doi.org/10.18565/therapy.2021.4.132-139
Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today. 2006;11-12:524-526. https://doi.org/10.1016/j.drudis.2006.04.003.
Walther J, Kirsch EM, Hellwig L, et al. Reinventing the penumbra — the emerging clockwork of a multi-modal mechanistic paradigm. Transl Stroke Res. 2022. Epub ahead of print. https://doi.org/10.1007/s12975-022-01090-9.
Martynov MU, Zhuravleva MV, Vasyukova NS, Kuznetsova EV, Kameneva TR. Oxidative stress in the pathogenesis of stroke and its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(1):16-27. (In Russ.). https://doi.org/10.17116/jnevro202312301116
Lankin VZ, Tikhaze AK, Belenkov YuN. Free radical processes are normal also at pathological states (A grant for doctors). The edition 2 corrected and added. M.: RKNPKMZRF; 2001. (In Russ.).
Semenkova GG, Kokoreva LV. Comparative effectiveness of myocardial cytoprotectors in chronic heart failure treatment. Russian Journal of Cardiology. 2007;(2):77-82. (In Russ.).
Silina EV, Rumyantseva SA, Bolevich SB. Regularities of a course of free radical processes and the forecast of an ischemic and hemorrhagic stroke. Magazine of neurology and psychiatry of S.S. Korsakov. 2011;12(2):36-42. (In Russ.).
Moiseyeva OM, Aleksandrova LA, Yemelyanov IV, Merkulova YI, Ivanova TG, Zhloba AA. Role of nitric oxide and its metabolites in the regulation of vascular tone in hypertensive disease. «Arterial’naya Gipertenziya» («Arterial Hypertension»). 2003;9(6):202-204. (In Russ.). https://doi.org/10.18705/1607-419X-2003-9-6-202-204
Statsenko ME, Turkina SV. Russian Journal of Cardiology and Cardiovascular Surgery. 2016;9(6):68-73. (In Russ.). https://doi.org/10.17116/kardio20169668-73.
Lankin VZ, Tikhaze AK, Kosach VYa, Konovalova GG, Kudryashova AV. Modification of low-density lipoproteins by low molecular weight carbonyl products of free-radical oxidation of lipids and carbohydrates plays a key role in atherosclerotic lesion of the vascular wall and in endothelial dysfunction. Acta Biomedica Scientifica. 2023;8(3):14-24. (In Russ.). https://doi.org/10.29413/ABS.2023-8.3.2
Lankin VZ, Sharapov MG, Tihaze AK, Goncharov RG, Antonova OA, Konovalova GG, Novoselov VI. Dicarbonyl-modified low-density lipoproteins are key inducers of LOX-1 and NOX1 gene expression in cultured human umbilical vein endotheliocytes. Biohimiâ. 2023;88:12:2517-2530. (In Russ.). https://doi.org/10.31857/S0320972523120138
Goryushkina OA, Vasilyev EM. Antioxidant therapy in correction of an oxidative stress at patients with coronary heart disease with a diabetes mellitus 2 types. Messenger of new medical technologies. 2013;2:156-158. (In Russ.).
Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation. 2004;110(8):894-896. https://doi.org/10.1161/01.CIR.0000139340.88769.D5
Mikhin VP. Cytoprotektion in cardiology: the achieved success and prospects. Part 1. The Russian Archives of Internal Medicine. 2014;(1):44-49. (In Russ.). https://doi.org/10.20514/2226-6704-2014-0-1-44-49
Mikhin VP. Cytoprotektion in cardiology: the achieved success and prospect. Cardiology. 2015;55:10:90-95. (In Russ.). https://doi.org/10.18565/cardio.2015.10.90-95
Knuuti J. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2020;25(2):3757. (In Russ.). https://doi.org/10.15829/1560-4071-2020-2-3757
Borovkova NYu. Use of a meksidol in cardiology — an additional and real way of protection of a myocardium. Kardionyyus. News of cardiology. 2017;11(25):7-8. (In Russ.).
Martynov AI, Tanashyan MM, Malyavin AG, Bogolepova AN, Borovkova NYu, Eliseeva LN, Zhuravleva MV, Zakharov VV, Koryagina NA, Mikhin VP, Osipova IV, Ostroumova OD, Pozdnyak AO, Portnyagina US, Statsenko ME, Tyrenko VV, Chesnikova AI. Resolution of the Expert Council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Therapy. 2023;9(10):148-158. (In Russ.). https://doi.org/10.18565/therapy.2023.10.148—158
Voronina TA, Ivanova EA. Combined administration of mexidol with known medicines. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(4):115-124. (In Russ.). https://doi.org/10.17116/jnevro2019119041115
Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2):35-39. (In Russ.).
Gupta DS, Bagwe Parab S, Kaur G. Promising effects of emoxypine and its succinate derivative in the management of various diseases-with insights on recent patent applications. Curr Res Pharmacol Drug Discov. 2022;3:100121. https://doi.org/10.1016/j.crphar.2022.100121
Glezer MG, Astashkin EI, Novikova MV. The mechanism of action of metabolic cytoprotector trimetazidine in acute ischemia-reperfusion injury. CardioSomatics. 2014;5:2:24-30. (In Russ.). https://doi.org/10.26442/CS45079
Mikhin VP. Kardiocytoprotektora — the new direction of clinical cardiology. The Russian Archives of Internal Medicine. 2011;(1):21-28. (In Russ.). https://doi.org/10.20514/2226-6704-2011-0-1-21-28
Voronina TA. Mexidol: the spectrum of pharmacological effects. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):86-90. (In Russ.).
Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
Borovkova NYu, Ilyina AS, Spasskiy AA, Borovkov NN, Kovaleva GV. Cytoprotective therapy for kidney injury in patients with ST-elevation myocardial infarction. Russian Journal of Cardiology and Cardiovascular Surgery. 2017;10(1):38-41. (In Russ.). https://doi.org/10.17116/kardio201710138-41
Ryngach EA, Tatarinova AA, Ryzhkova DV, et al. Antiarrhythmic potential of cardiocytoprotectors in the treatment of patients with coronary heart disease and ventricular arrhythmias. Russian Journal of Cardiology. 2016;(9):29-34. (In Russ.). https://doi.org/10.15829/1560-4071-2016-9-29-34
Ioseliani DG, Koledinsky AG, whether Kuchkina NV. Vozmozhno restriction of reperfusion damage of cardiomyocytes at endovascular restoration of a blood-groove in an infarktotvetstvenny artery by intra coronary introduction of metabolic cytoprotectors? International magazine of an intervention cardioangiology. 2006;11:11. (In Russ.).
Koledensky AG. Intra coronary therapy of an acute myocardial infarction the cardiocytoprotective drugs in a combination endovascular reperfusion of a myocardium: Dis. ... kand. med. nauk. M. 2010. (In Russ.).
Savelyeva VV. Therapy influence by a meksikor on indicators of an intracardial hemodynamics, physical tolerance, level of lipidperoxides and pro-natriuretic peptide in blood of ischemic heart disease patients with chronic heart failure: Dis. ... kand. med. nauk. Kursk. 2006. (In Russ.).
Shchulkin AV, Kazakhmedov ER, Galochkin SA, Tolkacheva VV, Kobalava ZD. Effects of mexidol in patients with chronic brain ischemia and chronic heart failure (II-III functional class). Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5):427-434. (In Russ.). https://doi.org/10.17116/kardio202013051427
Tolkacheva VV, Kazakhmedov ER, Kobalava ZD, Galochkin SA, Shchulkin AV. Effect of Mexidol on the quality of life and functional status of patients with chronic cerebral ischemia and chronic heart failure with reduced left ventricular ejection fraction. Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(1):80-89. (In Russ.). https://doi.org/10.17116/kardio20211401180
Sidorenko GI, Kommisarova SM, Zolotukhina SF, Petrovsky ME. Succinate ethylmethylhydroxypyridine use in treatment of patients with heart failure. Cardiology. 2011;6:44-48. (In Russ.).
Nechaeva GI, Kurochkina SD, Trotsenko AD, Bulakhova EIu. Mexidol in comlex therapy of a stable angina. Russian Journal of Cardiology and Cardiovascular Surgery. 2013;6(1):33-39. (In Russ.).
Nechayeva GI, Kurochkina SD, Semyonov EV, Tereshchenko YuV, Semenkin AA. Stenocardia with high level of anxiety. The Attending physician. 2017;3. (In Russ.).
Tolkacheva VV, Karapetyan LV, Khutsishvili NI, Galochkin SA, Kazakhmedov ER, Kobalava ZD. The effect of Mexidol on the improvement of cognitive status and quality of life parameters in the complex therapy of patients with chronic heart failure II—III functional class. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;16(4):362-373. (In Russ.). https://doi.org/10.17116/kardio202316041362
Tolkacheva VV, Karapetyan LV, Khutsishvili NI, Galochkin SA, Kazakhmedov ER, Kobalava ZD. The effect of mexidol as part of complex therapy on the perception of life in patients with heart failure. Russian Journal of Cardiology and Cardiovascular Surgery. 2023;16(6):642-652. (In Russ.). https://doi.org/10.17116/kardio202316061642
Martemianova EG. Clinical Aspects of ethylmethylhydroxypyridine succinate in elderly patients with cardiovasculat pathology. Cardiovascular Therapy and Prevention. 2018;17(2):57-62. (In Russ.). https://doi.org/10.15829/1728-8800-2018-2-57-62
Klimov AN, Nikulcheva NG. Exchange of lipids and lipoproteid and its violation. SPb.: St. Petersburg; 1999. (In Russ.).
Mikhin VP. Cytoprotektion in cardiology: the achieved success and prospects. Part 2. The Russian Archives of Internal Medicine. 2014;(2):33-40. (In Russ.). https://doi.org/10.20514/2226-6704-2014-0-2-33-40